Cisplatin plus vinorelbine (PVn) as a palliative regimen beyond second line for advanced breast cancer - A single institute experience

Yi Feng Wu, Tso Fu Wang, Sung Chao Chu, Kuan Po Huang, Chao Yuan Yo, Szu Chin Li, Chi Cheng Lee, Ruey Ho Kao

研究成果: 雜誌貢獻文章

摘要

Objectives: The combination of cisplatin and vinorelbine has been proved to be effective and safe in the therapy of advanced breast cancer. We reported the experience of treating advanced breast cancer with combination of cisplatin and vinorelbine (PVn) as second line palliative regimen in Hualien Buddhist Tzu Chi General Hospital. Study design: Retrospectively, we analyzed thirty patients who underwent the regimen of PVn between Oct. 2002 and Sep. 2008. Patients received cisplatin (75mg/m2) on day 1 and vinorelbine (25mg/m2) on day 1 and 8 by intravenous infusion in every three weeks. Treatment was repeated for up to six cycles. The effectiveness and complications of the regimen were analyzed. Results: Among 30 patients, there were 21 patients with objective responses (70%), including 4 complete responses (13.3%) and 17 partial responses (56.7%). Time to progression was 7.79 months, and overall survival was 13.2 months. Grade 3 or 4 neutropenia was observed in 15 patients (63.3%), and neutropenic fever developed in 11 patients (36.7%). There was no treatment-related mortality. Conclusion: The combination of cisplatin and vinorelbine is effective and with modest toxicity as a palliative regimen in advanced breast cancer.
原文英語
頁(從 - 到)344-351
頁數8
期刊Journal of Internal Medicine of Taiwan
22
發行號5
出版狀態已發佈 - 十月 1 2011
對外發佈Yes

指紋

Cisplatin
Breast Neoplasms
Neutropenia
Intravenous Infusions
General Hospitals
vinorelbine
Fever
Therapeutics
Survival
Mortality

ASJC Scopus subject areas

  • Internal Medicine

引用此文

Cisplatin plus vinorelbine (PVn) as a palliative regimen beyond second line for advanced breast cancer - A single institute experience. / Wu, Yi Feng; Wang, Tso Fu; Chu, Sung Chao; Huang, Kuan Po; Yo, Chao Yuan; Li, Szu Chin; Lee, Chi Cheng; Kao, Ruey Ho.

於: Journal of Internal Medicine of Taiwan, 卷 22, 編號 5, 01.10.2011, p. 344-351.

研究成果: 雜誌貢獻文章

Wu, Yi Feng ; Wang, Tso Fu ; Chu, Sung Chao ; Huang, Kuan Po ; Yo, Chao Yuan ; Li, Szu Chin ; Lee, Chi Cheng ; Kao, Ruey Ho. / Cisplatin plus vinorelbine (PVn) as a palliative regimen beyond second line for advanced breast cancer - A single institute experience. 於: Journal of Internal Medicine of Taiwan. 2011 ; 卷 22, 編號 5. 頁 344-351.
@article{14e4ca6991394fea928bc754aa4b8f1b,
title = "Cisplatin plus vinorelbine (PVn) as a palliative regimen beyond second line for advanced breast cancer - A single institute experience",
abstract = "Objectives: The combination of cisplatin and vinorelbine has been proved to be effective and safe in the therapy of advanced breast cancer. We reported the experience of treating advanced breast cancer with combination of cisplatin and vinorelbine (PVn) as second line palliative regimen in Hualien Buddhist Tzu Chi General Hospital. Study design: Retrospectively, we analyzed thirty patients who underwent the regimen of PVn between Oct. 2002 and Sep. 2008. Patients received cisplatin (75mg/m2) on day 1 and vinorelbine (25mg/m2) on day 1 and 8 by intravenous infusion in every three weeks. Treatment was repeated for up to six cycles. The effectiveness and complications of the regimen were analyzed. Results: Among 30 patients, there were 21 patients with objective responses (70{\%}), including 4 complete responses (13.3{\%}) and 17 partial responses (56.7{\%}). Time to progression was 7.79 months, and overall survival was 13.2 months. Grade 3 or 4 neutropenia was observed in 15 patients (63.3{\%}), and neutropenic fever developed in 11 patients (36.7{\%}). There was no treatment-related mortality. Conclusion: The combination of cisplatin and vinorelbine is effective and with modest toxicity as a palliative regimen in advanced breast cancer.",
keywords = "Advanced breast cancer, Chemotherapy, Cisplatin, Palliative, Vinorelbine",
author = "Wu, {Yi Feng} and Wang, {Tso Fu} and Chu, {Sung Chao} and Huang, {Kuan Po} and Yo, {Chao Yuan} and Li, {Szu Chin} and Lee, {Chi Cheng} and Kao, {Ruey Ho}",
year = "2011",
month = "10",
day = "1",
language = "English",
volume = "22",
pages = "344--351",
journal = "Journal of Internal Medicine of Taiwan",
issn = "1016-7390",
publisher = "臺灣內科醫學會",
number = "5",

}

TY - JOUR

T1 - Cisplatin plus vinorelbine (PVn) as a palliative regimen beyond second line for advanced breast cancer - A single institute experience

AU - Wu, Yi Feng

AU - Wang, Tso Fu

AU - Chu, Sung Chao

AU - Huang, Kuan Po

AU - Yo, Chao Yuan

AU - Li, Szu Chin

AU - Lee, Chi Cheng

AU - Kao, Ruey Ho

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Objectives: The combination of cisplatin and vinorelbine has been proved to be effective and safe in the therapy of advanced breast cancer. We reported the experience of treating advanced breast cancer with combination of cisplatin and vinorelbine (PVn) as second line palliative regimen in Hualien Buddhist Tzu Chi General Hospital. Study design: Retrospectively, we analyzed thirty patients who underwent the regimen of PVn between Oct. 2002 and Sep. 2008. Patients received cisplatin (75mg/m2) on day 1 and vinorelbine (25mg/m2) on day 1 and 8 by intravenous infusion in every three weeks. Treatment was repeated for up to six cycles. The effectiveness and complications of the regimen were analyzed. Results: Among 30 patients, there were 21 patients with objective responses (70%), including 4 complete responses (13.3%) and 17 partial responses (56.7%). Time to progression was 7.79 months, and overall survival was 13.2 months. Grade 3 or 4 neutropenia was observed in 15 patients (63.3%), and neutropenic fever developed in 11 patients (36.7%). There was no treatment-related mortality. Conclusion: The combination of cisplatin and vinorelbine is effective and with modest toxicity as a palliative regimen in advanced breast cancer.

AB - Objectives: The combination of cisplatin and vinorelbine has been proved to be effective and safe in the therapy of advanced breast cancer. We reported the experience of treating advanced breast cancer with combination of cisplatin and vinorelbine (PVn) as second line palliative regimen in Hualien Buddhist Tzu Chi General Hospital. Study design: Retrospectively, we analyzed thirty patients who underwent the regimen of PVn between Oct. 2002 and Sep. 2008. Patients received cisplatin (75mg/m2) on day 1 and vinorelbine (25mg/m2) on day 1 and 8 by intravenous infusion in every three weeks. Treatment was repeated for up to six cycles. The effectiveness and complications of the regimen were analyzed. Results: Among 30 patients, there were 21 patients with objective responses (70%), including 4 complete responses (13.3%) and 17 partial responses (56.7%). Time to progression was 7.79 months, and overall survival was 13.2 months. Grade 3 or 4 neutropenia was observed in 15 patients (63.3%), and neutropenic fever developed in 11 patients (36.7%). There was no treatment-related mortality. Conclusion: The combination of cisplatin and vinorelbine is effective and with modest toxicity as a palliative regimen in advanced breast cancer.

KW - Advanced breast cancer

KW - Chemotherapy

KW - Cisplatin

KW - Palliative

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=84255166709&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84255166709&partnerID=8YFLogxK

M3 - Article

VL - 22

SP - 344

EP - 351

JO - Journal of Internal Medicine of Taiwan

JF - Journal of Internal Medicine of Taiwan

SN - 1016-7390

IS - 5

ER -